Humabiologics has unveiled a new research-grade human collagen product designed to support scientists facing significant funding constraints in the life sciences sector. The innovative biomaterial, part of the company's HumaDerm product line, offers researchers an ethically sourced and cost-effective alternative to animal-derived materials.
The launch addresses critical challenges in scientific research, particularly amid federal budget cuts to the National Institutes of Health (NIH) and National Science Foundation (NSF) grants. By providing high-quality human collagen at a price point lower than animal alternatives, Humabiologics aims to enable researchers to conduct more physiologically relevant studies without compromising their limited budgets.
Mohammad Albanna, PhD, Founder and CEO of Humabiologics, emphasized the product's significance, noting that researchers have been struggling to maintain scientific momentum due to financial limitations. The human collagen is sourced from FDA-registered and AATB-accredited tissue banks, utilizing tissues that are not suitable for transplantation but can still contribute to scientific advancement.
Tim Bertram from the National Science Foundation Piedmont Triad Regenerative Medicine Engine highlighted the potential impact, describing the product as a pivotal development that eliminates cost barriers historically preventing researchers from using clinically relevant materials. The collagen is particularly valuable for regenerative medicine, drug testing, tissue models, and organ-on-a-chip applications.
This product launch builds on Humabiologics' recent grant from the Piedmont Triad Regenerative Medicine Engine and represents a collaborative effort with institutions like the Wake Forest Institute for Regenerative Medicine. By making human biomaterials more accessible, the company aims to accelerate research translation and potentially improve predictive models for human outcomes.
